未登录

C

Chris Skedgel

iqvia

H指数:24

被引数:1,915

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Considering Severity in Health Technology Assessment: Can We Do Better?

考虑卫生技术评估的严重性: 我们能做得更好吗？

VALUE IN HEALTH

IF6

2022-08-0120

OAAI

How Do People with Experience of Infertility Value Different Aspects of Assistive Reproductive Therapy? Results from a Multi-Country Discrete Choice Experiment

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH

IF3.1

2021-12-238

OAAI

Towards a New Understanding of Unmet Medical Need

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2021-06-1810

OAAI

A Longitudinal Study of Ambulatory Physician Encounters, Emergency Room Visits, and Hospitalizations by Patients with Rheumatoid Arthritis: A 13-year Population Health Study

JOURNAL OF RHEUMATOLOGY

IF3.4

2017-08-017

OAAI

Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review

BREAST CANCER RESEARCH AND TREATMENT

IF3

2016-08-3011

PREAI

Utilization of Ambulatory Physician Encounters, Emergency Room Visits, and Hospitalizations by Systemic Lupus Erythematosus Patients: A 13-Year Population Health Study

ARTHRITIS CARE & RESEARCH

IF3.3

2016-07-2216

OAAI

Adherence to Guidelines and the Screening Tool of Older Persons' Potentially Inappropriate Prescriptions Criteria for Colchicine Dosing for Gout Treatment in Beneficiaries of the Nova Scotia Seniors' Pharmacare Program

CLINICAL THERAPEUTICS

IF3.6

2015-10-011

OAAI

Societal Preferences for Distributive Justice in the Allocation of Health Care Resources: A Latent Class Discrete Choice Experiment

MEDICAL DECISION MAKING

IF2.3

2014-08-2147

OAAI

Constant-Sum Paired Comparisons for Eliciting Stated Preferences: A Tutorial

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH

IF3.1

2014-07-2012

PREAI

Should adjuvant zoledronic acid be used in early-stage, endocrine-sensitive breast cancer?

CANCER RESEARCH

IF16.6

2013-12-150

PRE

Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer

CANCER RESEARCH

IF16.6

2013-12-150

PRE

A MORTALITY ADVANTAGE AT 2 YEARS WHEN ATTENDING A COMMUNITY BASED CR PROGRAM WITH MINIMAL AND INSIGNIFICANT HEALTHCARE COSTS. NOW THAT'S A DEAL!

CANADIAN JOURNAL OF CARDIOLOGY

IF5.3

2013-10-011

PREAI

Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?

曲妥珠单抗辅助治疗是治疗她-2/neu阳性T1bN0乳腺癌的一种经济有效的方法吗？

ANNALS OF ONCOLOGY

IF65.4

2013-07-0114

OAAI

Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences

HEALTH EXPECTATIONS

IF3.2

2013-06-1228

OAAI

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

BREAST CANCER RESEARCH AND TREATMENT

IF3

2012-02-2452

PREAI

Simultaneous Liver Kidney Transplantation: A Medical Decision Analysis

同时进行肝肾移植的医疗决策分析

TRANSPLANTATION

IF5

2011-01-1530

OAAI

Modeling for Response Predictive Factors in Adjuvant Endocrine Therapy: Impact on Preferential Benefits of Tamoxifen and Aromatase Inhibitors

CANCER RESEARCH

IF16.6

2010-12-010

PRE

Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2010-05-207

PREAI

The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial

VALUE IN HEALTH

IF6

2009-07-0127

OAAI

Gout in the Elderly - A Population Health Study

JOURNAL OF RHEUMATOLOGY

IF3.4

2009-03-1334

OAAI